目的 探讨心可舒丸联合贝尼地平治疗变异型心绞痛的临床疗效。方法 选择2020年11月—2023年11月青岛市第八人民医院收治的80例变异型心绞痛患者为研究对象，抽签法随机分为对照组（40例）和治疗组（40例）。对照组口服盐酸贝尼地平片，1次/d。在对照组的基础上，治疗组口服心可舒丸，4粒/次，3次/d。两组患者连续治疗6周。观察两组患者临床疗效，比较治疗前后两组患者临床症状评分，心绞痛发作持续时间和发作次数，血清C反应蛋白（CRP）、白细胞介素-6（IL-6）、可溶性细胞间黏附分子-1（sICAM-1）、内皮素-1（ET-1）、一氧化氮（NO）、心肌肌钙蛋白Ⅰ（cTnI）水平。结果 与对照组相比，治疗组总有效率明显升高（95.00% vs 80.00%，P＜0.05）。治疗后，两组患者胸闷、胸痛及心悸评分明显降低（P＜0.05），且治疗组评分明显低于对照组（P＜0.05）。治疗后，两组患者心绞痛发作持续时间和发作次数均明显下降（P＜0.05），且与对照组相比，治疗组降低更明显（P＜0.05）。治疗后，两组患者血清CRP、IL-6、sICAM-1、ET-1和cTnI水平明显降低，而NO水平明显升高（P＜0.05），且与对照组相比，治疗组血清学水平改善更明显（P＜0.05）。结论 心可舒丸联合贝尼地平治疗变异型心绞痛的临床疗效较好，有助于改善临床症状，减轻心绞痛，改善血清炎性因子和ET-1、NO、cTnI水平，且具有较好的安全性。

Objective To investigate the clinical efficacy of Xinkeshu Pills combined with benidipine in treatment of variant angina pectoris. Methods Patients (80 cases) with variant angina pectoris in Qingdao Eighth People’s Hospital from November 2020 to November 2023 were divided into control (40 cases) and treatment (40 cases) group by drawing lots. Patients in the control group were po administered with Benidipine Hydrochloride Tablets, once dalily. Patients in the treatment group were po administered with Xinkeshu Pills on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical evaluations were evaluated, the clinical symptom scores, duration and f frequency of angina attacks, the levels of serum CRP, IL-6, sICAM-1, ET-1, NO and cTnI in two groups before and after treatment were compared. Results Compared with the control group, the total clinical effective rate of the treatment group was significantly increased (95.00% vs 80.00%, P < 0.05). After treatment, the scores of chest tightness, chest pain, and palpitations in two groups were significantly reduced (P < 0.05), and the scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the duration and frequency of angina attacks in two groups were significantly decreased (P < 0.05), and compared with the control group, the treatment group showed a more significant decrease (P < 0.05). After treatment, the levels of serum CRP, IL-6, sICAM-1, ET-1, and cTnI in two groups of patients were significantly reduced, while the level of NO was significantly increased (P < 0.05). Compared with the control group, the serum levels in the treatment group improved more significantly (P < 0.05). Conclusion The clinical efficacy of Xinkeshu Pills combined with benidipine in the treatment of variant angina pectoris is significant, which helps to improve clinical symptoms, alleviate angina pectoris, improve serum inflammatory factors and ET-1, NO, cTnI levels, and has good safety.

R972

山东省医学会临床科研资金-齐鲁专项（YXH2021ZX02210）